{"url_path":"/sec/qnrx/8-k/2026-06-04/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/1671502/0001104659-26-070501-index.html","accession_number":"0001104659-26-070501","cik":"0001671502","ticker":"QNRX","issuer_name":"Quoin Pharmaceuticals Ltd.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1671502/0001104659-26-070501-index.html","primary_entity_key":"0001671502","primary_entity_name":"Quoin Pharmaceuticals, Ltd."},"word_count":95,"has_tables":true,"body_markdown":"**Item 9.01. Financial\nStatements and Exhibits.**\n\n** **\n\n(d)\nExhibits.\n\n \n\nThe following exhibits\nare filed or furnished, as applicable, with this Report:\n\n \n\n**Exhibit\nNumber**\n \n**Description**\n\n \n \n \n\n[99.1](tm2616916d1_ex99-1.htm)\n \n[Press Release of the Company, dated June 4, 2026](tm2616916d1_ex99-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n  \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.\n\n \n\nDate: June 4, 2026\n**QUOIN PHARMACEUTICALS LTD.**\n\n \n \n\n \nBy:\n/s/ Michael Myers\n\n \nName:\nDr. Michael Myers\n\n \nTitle:\nChief Executive Officer"}